Evidence map›Paper›PMID 38254356›Full record

ArticleAnimals : an open access journal from MDPI2024

Ursolic Acid Induces Beneficial Changes in Skeletal Muscle mRNA Expression and Increases Exercise Participation and Performance in Dogs with Age-Related Muscle Atrophy.

Scott M Ebert, Celine S Nicolas, Paul Schreiber, Jaime G Lopez, Alan T Taylor, Andrew R Judge, Sarah M Judge, Blake B Rasmussen, John J Talley, Christophe A Rème and 1 more

Open access · goldAbstract read
In one paragraph

Article in Animals : an open access journal from MDPI, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Anti-Atrophic Effects of Dichotomine B fromMolecules (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Scott M EbertEmmyon, Inc., Rochester, MN 55902, USA.
Celine S NicolasMarket Unit Petfood Petcare, Virbac SA, 06511 Carros, France.ORCID 0000-0002-5285-5946
Paul SchreiberResearch & Development-Biopharmacy Department, Virbac SA, 06511 Carros, France.
Jaime G LopezUS Petcare Innovation, Virbac NA, Westlake, TX 76262, USA.
Alan T TaylorInnovation, Business Development, Virbac NA, Westlake, TX 76262, USA.
Andrew R JudgeEmmyon, Inc., Rochester, MN 55902, USA.ORCID 0000-0002-4488-291X
Sarah M JudgeEmmyon, Inc., Rochester, MN 55902, USA.
Blake B RasmussenEmmyon, Inc., Rochester, MN 55902, USA.ORCID 0000-0001-7854-5375
John J TalleyEmmyon, Inc., Rochester, MN 55902, USA.
Christophe A RèmeMarket Unit Petfood Petcare, Virbac SA, 06511 Carros, France.
Christopher M AdamsEmmyon, Inc., Rochester, MN 55902, USA.
Virbac (France) · FRMayo Clinic in Arizona · USUniversity of Florida · USThe University of Texas Health Science Center at San Antonio · US

Funding

TRANSGENIC COREP30AG013319 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JAMES FLOYD NELSON · 1995 to 2026
$30.6M
San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon, Elena Volpi · 2015 to 2026
$14.1M
FOXO signaling and skeletal muscle atrophyR01AR060209 · NIAMS · UNIVERSITY OF FLORIDA · PI JUDGE, ANDREW ROBERT · 2011 to 2021
$4.2M
Novel Signaling Pathways Underlying Skeletal Muscle AtrophyR01AG060637 · NIA · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2018 to 2022
$2.6M
The Complement System and Cancer CachexiaR01AR081648 · NIAMS · UNIVERSITY OF FLORIDA · PI Carl Atkinson, Andrew Robert Judge · 2022 to 2026
$2.3M
Sex-specific determinants of early-phase recovery from skeletal muscle disuse.R01AG064386 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RASMUSSEN, BLAKE B · 2019 to 2022
$2.0M
Development of novel therapeutics for cancer cachexiaR44CA277853 · NCI · EMMYON, INC. · PI ADAMS, CHRISTOPHER M, EBERT, SCOTT MATTHEW · 2023 to 2024
$2.0M
Matricellular proteins of the CNN family as regulators of tumor-induced cachexiaR01CA270025 · NCI · UNIVERSITY OF FLORIDA · PI Sarah M Judge · 2023 to 2026
$1.9M
Discovery of Novel Pharmaceutical Agents for Skeletal Muscle AtrophyR44AR069400 · NIAMS · EMMYON, INC. · PI ADAMS, CHRISTOPHER M, EBERT, SCOTT MATTHEW · 2020 to 2021
$1.5M
NCI NIH HHS R01 CA270025NCI NIH HHS R44 CA277853NIAMS NIH HHS R01 AR060209NIAMS NIH HHS R01 AR081648NIAMS NIH HHS R44 AR069400NIA NIH HHS P30 AG013319NIA NIH HHS P30 AG044271NIA NIH HHS R01 AG060637NIA NIH HHS R01 AG064386NIH HHS P30AG013319NIH HHS P30AG044271NIH HHS R01AG060637NIH HHS R01AG064386NIH HHS R01AR060209NIH HHS R01AR081648NIH HHS R01CA270025NIH HHS R44CA277853
6 · The paper itself

Abstract

Muscle atrophy and weakness are prevalent and debilitating conditions in dogs that cannot be reliably prevented or treated by current approaches. In non-canine species, the natural dietary compound ursolic acid inhibits molecular mechanisms of muscle atrophy, leading to improvements in muscle health. To begin to translate ursolic acid to canine health, we developed a novel ursolic acid dietary supplement for dogs and confirmed its safety and tolerability in dogs. We then conducted a randomized, placebo-controlled, proof-of-concept efficacy study in older beagles with age-related muscle atrophy, also known as sarcopenia. Animals received placebo or ursolic acid dietary supplements once a day for 60 days. To assess the study's primary outcome, we biopsied the quadriceps muscle and quantified atrophy-associated mRNA expression. Additionally, to determine whether the molecular effects of ursolic acid might have functional correlates consistent with improvements in muscle health, we assessed secondary outcomes of exercise participation and T-maze performance. Importantly, in canine skeletal muscle, ursolic acid inhibited numerous mRNA expression changes that are known to promote muscle atrophy and weakness. Furthermore, ursolic acid significantly improved exercise participation and T-maze performance. These findings identify ursolic acid as a natural dietary compound that inhibits molecular mechanisms of muscle atrophy and improves functional performance in dogs.

Indexed as

activitycachexiacaninedietary supplementdogexercisemuscle atrophysarcopeniaskeletal muscleursolic acid

Identifiers

PMID38254356
PMCPMC10812546
OpenAlexW4390669138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.